Development of Novel, Selective, Orally Available Small Molecule CDK9 Inhibitors for Prostate Cancer Therapy - Mechanistic Studies
ISEF · 2022 Translational Medical Science
Overview
Development of Novel, Selective, Orally Available Small Molecule CDK9 Inhibitors for Prostate Cancer Therapy - Mechanistic studies Abstract: Amplification of N-MYC causes its overexpression in Neuroendocrine Prostate Cancer (NEPC) patients, and it is a rare lethal subtype of cancer detected in 2% of all Prostate Cancers (PC) and over 10-17% of mCRPC (Metastatic Castration-Resistant PC) patients. N-MYC and activated CDK9 function as oncogenic drivers sufficient to transform human-derived prostate cancer cells to take on NEPC phenotypic changes resulting in a more aggressive disease identified in late-stage human PC patients. Additionally, N-MYC is associated with tumor resistance, and its downregulation through CDK9 inhibitors lessens tumor burden. Our efforts in this study proved that the targeting of N-NYC as a driver of NEPC with CDK9 inhibitors such as OLX-3030 and its series could be a viable approach for therapeutic intervention of mCRPC and NEPCs. We performed the western blot experiments utilizing the novel small molecule CDK9 inhibitor OLX-3030, its analogues, and reference compound AZD-4573 against prostate cancer cells; DU145 including NEPC cell lines; 22RV1 and LASCPC01. Our lead CDK9 inhibitor OLX-3030 exhibited potent activity in inhibiting DU-145, 22RV1, and LASCPC-01 cell lines. These results were comparable to that of the reference compound AZD-4574 which is a clinical-stage agent in development by AstraZeneca. In summary, OLX-3030 and its analogues displayed promising activities in both androgen receptor-positive, and NEPC cells by down-regulating N-MYC, C-MYC, and super-enhancer genes such as MCL-1. We conclude that OLX-3030 had the appropriate qualities for development as a pre-clinical candidate.
Competition history
- ISEF 2022
Resources
Related projects
ISEF · 2025
Assessing Novel RIPK2-MKK7 Interaction Inhibitors in Prostate Cancer Cell Lines
ISEF · 2025
Targeting Cap-Independent Translation in c-MYC mRNA: A Novel Small Molecule Approach for Cancer Therapy
AJAS · 2025
CDK9-Specific PROTAC 2 Treatment Sensitizes Pancreatic Cancer Cells to Navitoclax
CSEF · 2018
Analyzing the Effects of Interferon Signaling as a Novel Approach to Neuroendocrine Prostate Cancer Therapy
ISEF · 2025
Overcoming Docetaxel Resistance in Prostate Cancer
ISEF · 2020
Examining Mechanisms of Resistance in Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells
ISEF · 2024
The Therapeutic Potential of Suppressing Chemokine Receptor CXCR4 Pathway Components in Small Cell Lung Cancer (SCLC) Through First-Generation Potent Inhibitors
ISEF · 2020
Decoding the Molecular Dynamics of ASH1L in Cancer Using NMR for Novel KMTase Inhibitor
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair